SCHEMBL21883705

SCHEMBL21883705

COCOc1c(C#N)cccc1SC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.34
GAA P10253 3/20 0.34
LMNA P02545 2/20 0.34
ALDH1A1 P00352 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
AR P10275 2/20 0.34
PTPN1 P18031 1/20 0.33
POLB P06746 2/20 0.33
EGFR P00533 1/20 0.33
ERBB2 P04626 1/20 0.33
XDH P47989 1/20 0.33
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
HPGD P15428 2/20 0.32
KMT2A Q03164 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22096793 0.86 LMNA (0.39) TDP1GAALMNAALDH1A1SMN1; SMN2
SCHEMBL22096831 0.83 GAA (0.35) TDP1GAALMNAALDH1A1SMN1; SMN2
SCHEMBL22096797 0.80 LMNA (0.39) TDP1GAALMNAALDH1A1SMN1; SMN2
SCHEMBL23269915 0.79 PTPN1 (0.49) GAALMNAARPTPN1EGFR
SCHEMBL21143326 0.78 EGFR (0.39) GAAALDH1A1PTPN1POLBEGFR
SCHEMBL30509819 0.78 EGFR (0.39) GAAALDH1A1PTPN1POLBEGFR
SCHEMBL28289636 0.78 AR (0.39) GAAALDH1A1ARPTPN1POLB
SCHEMBL21884012 0.76 TSHR (0.38) GAAALDH1A1ARPTPN1POLB
SCHEMBL19768959 0.75 EGFR (0.34) GAALMNASMN1; SMN2ARPTPN1
SCHEMBL28252982 0.75 PTPN1 (0.36) GAAALDH1A1PTPN1POLBEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10875839-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-12-29 US disclosed
US-20200190053-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2020-06-18 US disclosed
US-10597377-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200190053-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 TDP1 2824/4885GAA 198/4885LMNA 3475/4885
US-10597377-B2 Somatostatin modulators and uses thereof SSTR5, SSTR2, SSTR4 TDP1 2824/4885GAA 198/4885LMNA 3475/4885
US-10875839-B2 Somatostatin modulators and uses thereof SSTR5, SSTR2, SSTR4 TDP1 2824/4885GAA 198/4885LMNA 3475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.